How do Hashimoto's thyroiditis and Graves disease differ?

How Hashimoto's Thyroiditis and Graves' Disease Differ

Hashimoto's thyroiditis causes hypothyroidism through T cell-mediated destruction of thyroid tissue with elevated anti-TPO and anti-thyroglobulin antibodies, while Graves' disease causes hyperthyroidism through TSH receptor-stimulating antibodies (TRAb) that activate thyroid hormone production.

Fundamental Immunologic Distinction

The core difference lies in the autoimmune mechanism and resulting thyroid function:

Hashimoto's Thyroiditis

• Mechanism: Predominantly CD8+ T cell-mediated cytotoxic destruction of thyroid follicular cells 1
• Immune profile: Th1-driven cellular immunity with antibody-dependent cytotoxicity 2
• Antibodies: Anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies that facilitate tissue destruction 3
• T cell pattern: Low CD4+ T cells, markedly increased CD8+ T cells (20.54% vs 0.65% in controls) with cytotoxic properties 1
• Clinical result: Progressive thyroid destruction leading to hypothyroidism

Graves' Disease

• Mechanism: TSH receptor-stimulating antibodies (TRAb/TSI) that bind and activate the TSH receptor 4
• Immune profile: Th2-driven humoral immunity with antibody-mediated stimulation 2
• Antibodies: TRAb/TSI that mimic TSH action, driving excessive thyroid hormone production
• T cell pattern: Increased CD4+ T cells (3.17%) with plasma cells producing stimulatory antibodies 1
• Clinical result: Thyroid hyperfunction causing hyperthyroidism

Genetic and HLA Associations

The diseases show distinct HLA class II associations 5:

• Hashimoto's: Strong association with DR4 (DRB104-DQB103-DQA1*03, OR=1.98, P=6.79×10⁻⁷), only borderline DR3 association
• Graves': Strong association with DR3 (DRB103-DQB102-DQA1*05), weaker DR4 association
• Both: Protective effects from DR7 and DR13

This genetic divergence partially explains why these diseases manifest differently despite sharing autoimmune thyroid pathology 5.

Clinical Presentation

Hashimoto's Thyroiditis

• Fatigue, weight gain, cold intolerance, constipation
• Firm, diffusely enlarged goiter (may be atrophic in late stages)
• Gradual onset of hypothyroid symptoms
• May have initial transient hyperthyroid phase ("hashitoxicosis") due to thyroid destruction releasing stored hormone 2

Graves' Disease

• Weight loss, heat intolerance, palpitations, tremor, anxiety
• Diffuse goiter with bruit
• Graves' ophthalmopathy (25-50% of cases) - specific to Graves', not seen in Hashimoto's 4
• Pretibial myxedema (rare but specific)
• More acute onset of symptoms

Diagnostic Approach

Critical diagnostic pitfall: Suppressed TSH alone does not distinguish between destructive thyrotoxicosis (Hashimoto's variant) and Graves' disease 2. Mandatory TRAb testing is essential to avoid misdiagnosis and inappropriate antithyroid drug therapy 2.

Hashimoto's Diagnosis

• Elevated TSH, low free T4
• Positive anti-TPO (most sensitive, 90-95% of cases) and/or anti-thyroglobulin antibodies
• TRAb/TSI negative (critical distinguishing feature)
• Ultrasound: Heterogeneous hypoechoic pattern, reduced vascularity, possible thyroid atrophy 6

Graves' Diagnosis

• Suppressed TSH (<0.1 mIU/L), elevated free T4 and T3 7
• Positive TRAb/TSI (diagnostic hallmark) 4
• Anti-TPO may be positive (30-50% overlap)
• Radioactive iodine uptake: Elevated and diffuse (distinguishes from destructive thyroiditis) 7
• Ultrasound: Diffuse enlargement, increased vascularity ("thyroid inferno"), multinodular pattern more common 6

Role of Regulatory T Cells

Both diseases show deficiency in CD4+CD25+FOXP3+ regulatory T cells (Tregs) compared to healthy controls 8, but:

• Graves' disease shows lower absolute Treg numbers than Hashimoto's 8
• Treg depletion in animal models induces Hashimoto's-like thyroiditis with hypothyroidism, not Graves' hyperthyroidism 9
• This suggests Treg dysfunction may be more critical in preventing destructive thyroiditis than preventing stimulatory antibody production

Disease Transition and Overlap

Rare conversion from Hashimoto's to Graves' can occur (uncommon, representing immune shift from Th1 to Th2) 6:

• These "switchers" have milder hyperthyroidism with lower TRAb levels
• Higher remission rates with antithyroid drugs (ATD)
• More prone to spontaneous early hypothyroidism after ATD
• Ultrasound shows thyroid hypotrophy and reduced vascularity despite hyperthyroidism 6

More commonly, Graves' disease progresses to hypothyroidism when thyroid destruction becomes extensive, representing disease evolution rather than true conversion 9.

Treatment Implications

Hashimoto's Thyroiditis

• Levothyroxine replacement therapy (lifelong in most cases) 3
• Adjunctive selenium and vitamin D supplementation may be beneficial 3
• No role for antithyroid drugs, radioactive iodine, or surgery (unless compressive goiter)

Graves' Disease

• Three definitive options: Antithyroid drugs (methimazole preferred), radioactive iodine, or thyroidectomy 4
• Beta-blockers for symptomatic control
• Special considerations for ophthalmopathy (corticosteroids with radioactive iodine if active eye disease) 4

Critical error to avoid: Treating destructive thyrotoxicosis in Hashimoto's patients with antithyroid drugs accelerates progression to hypothyroidism and provides no benefit, as the mechanism is thyroid destruction, not overproduction 2. This misdiagnosis occurred in 80% of cases in one series, emphasizing the importance of TRAb testing 2.